NEW YORK (GenomeWeb News) – A clinical study targeting dysferlinopathy expected to cost $3 million has exceeded its patient recruitment goal, the Jain Foundation, which is funding the study, said today.

The Clinical Outcome Study for Dysferlinopathy has recruited 193 patients, passing the original goal of 150. The three-year project is being conducted in 14 centers and is led by Kate Bushby at Newcastle University and Laura Rufibach at the Jain Foundation.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.